New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease Marco Meglio

Published Date: 04 Dec 2025

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reducing social media to an hour a day boosts young people's self-image.

2.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

3.

The pandemic had little impact on mental health symptoms.

4.

FDA Approves New Bladder Cancer First-Line Standard of Care.

5.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot